Developer docs
API playgroundTry for free, no card

Search company profiles

Microbiotica

Full company profile

uuid0000j5q

Namestring
Microbiotica
Legal namestring
Microbiotica Limited
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Microbiotica Limited is a Cambridge, UK-based, clinical-stage biopharmaceutical company founded in 2016 as a spin-out from the Wellcome Sanger Institute. It develops orally administered live biotherapeutic products (LBPs), which are defined consortia of commensal gut bacteria, for inflammatory bowel disease and immuno-oncology. The lead asset MB310 is an eight-strain capsule for ulcerative colitis that delivered 63.2% clinical remission versus 30% on placebo in the Phase 1b COMPOSER-1 trial; MB097 is a nine-strain capsule being evaluated in combination with MSD's KEYTRUDA in advanced melanoma patients with primary resistance to anti-PD-1 therapy in the Phase 1b MELODY-1 trial.

The company's core technology is a clinic-led microbiome profiling platform that combines mass culturing, metagenomics and machine learning to identify bacteria associated with favorable outcomes in specific patient populations. MB310 has been characterized with three independent mechanisms of action, including a novel protein (IZOR) supporting gut barrier healing and immune regulation; MB097's strains induce dendritic-cell IL-12 production that drives cytotoxic T-cell and NK-cell tumor killing. The company has assembled an unusually rich clinical dataset, including the Cancer Research UK MELRESIST and MITRE studies (up to 1,800 patients) and samples from University of Adelaide FMT studies that seeded MB310.

Microbiotica is pre-revenue and funds operations from equity (over £62 million raised to date, including a $67 million 2022 Series B co-led by Tencent). The commercial model is licensing- and partnership-driven: the company relies on MSD for KEYTRUDA supply, the Crohn's & Colitis Foundation for cGMP manufacture of MB310, and previously executed a $534 million Genentech IBD collaboration. Customers are therefore strategic pharma partners rather than payers, and patients enrolled in clinical trials are end users, not revenue sources. Geographic footprint spans the UK, France, Italy, Spain, Austria, Bulgaria and Poland through trial sites.

Short descriptiontext

Microbiotica is a Cambridge, UK-based clinical-stage biopharmaceutical company developing orally administered live biotherapeutic products (LBPs) for ulcerative colitis and immuno-oncology, using a proprietary clinic-led microbiome profiling platform to identify defined bacterial consortia with characterized mechanisms of action.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbiome therapeutics, live biotherapeutic products, ulcerative colitis pipeline, immuno-oncology microbiome, defined bacterial consortia
Industry3 codes
PRIMARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Microbiome Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biopharma company. Revenue generation anticipated through eventual product commercialization following regulatory approval, with potential licensing/partnership deals for late-stage development and commercialization rights.

microbiotica.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Microbiotica discovers and develops precision microbiome medicines in the form of oral live biotherapeutic products (LBPs) - defined consortia of gut bacteria identified through its clinic-led discovery platform. Its lead clinical-stage assets are MB310 (eight-strain consortium) for mild-to-moderate ulcerative colitis and MB097 (nine-strain consortium) for advanced melanoma in combination with KEYTRUDA, both in Phase 1b clinical trials. The company's revenue path is through licensing, co-development and partnership agreements with pharmaceutical companies rather than direct product sales today.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 63.2% clinical remission rate with MB310 vs 30% placebo in ulcerative colitis patients
+2 more records
Product overview1 text field

Microbiotica is a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs). The company operates a clinic-led discovery platform that uses microbiome profiling, bioinformatics, and machine learning to identify bacteria associated with favorable clinical outcomes in specific patient populations. The core product portfolio includes MB310, a defined consortium of eight bacterial strains for ulcerative colitis treatment, and MB097, a defined consortium of nine bacterial strains designed to enhance immune checkpoint inhibitor efficacy in advanced melanoma. Both products are orally administered live biotherapeutic products.

Product and service2 records
1MB310
CategoryMicrobiome Therapeutics - Inflammatory Bowel Disease
Description

MB310 is Microbiotica's lead clinical asset: a once-daily, orally administered live biotherapeutic product (LBP) consisting of a defined consortium of eight strains of commensal gut bacteria, being developed as a precision microbiome medicine for mild-to-moderate ulcerative colitis. It is currently in the COMPOSER-1 Phase 1b clinical trial and has reported positive topline data including 63.2% clinical remission in the per-protocol population.

2MB097
CategoryMicrobiome Therapeutics - Immuno-oncology
Description

MB097 is Microbiotica's immuno-oncology live biotherapeutic product: a once-daily, orally administered LBP consisting of a defined consortium of nine strains of gut bacteria being developed in combination with MSD's KEYTRUDA (pembrolizumab) for advanced melanoma. It is in the MELODY-1 Phase 1b clinical trial and has reported positive results including an objective response rate approximately double that of pembrolizumab monotherapy, with a characterised IL-12 induction mechanism linked to the IZOR bacterial outer-membrane protein.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-06-18
Description

Collaboration with Dr Sam Costello's team to analyze clinical samples from FMT study in UC patients. Led to identification of MB310 bacterial strains. Financial details not disclosed.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

$534 million strategic collaboration to discover, develop and commercialize biomarkers, targets and medicines for inflammatory bowel disease. Microbiotica delivered successfully microbial biomarker signatures of drug response. Now listed as previous collaboration.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial supply collaboration where MSD supplies KEYTRUDA (pembrolizumab) for use in evaluating MB097 in combination with anti-PD-1 therapy in melanoma patients with primary resistance to immunotherapy. Microbiotica is study sponsor.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration supporting cGMP manufacture of MB310, enabling IND application and progression into first-in-human clinical trials. Foundation provides expertise and network in ulcerative colitis disease area.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Landmark partnership to identify and develop microbiome co-therapies and biomarkers for cancer patients receiving immune checkpoint inhibitors. Includes MELRESIST melanoma study and MITRE study (1,800 patients) in melanoma, lung, and renal cancer.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing defined consortia of live bacteria for immune-mediated diseases including IBD and oncology indications. Closely comparable to Microbiotica on product format (defined bacterial consortia), target indications, and clinical-stage development profile.

TypeDirect peer
Description

Pioneer in microbiome therapeutics with FDA-approved VOWST for recurrent C. difficile infection and pipeline programs in IBD and oncology. Direct competitor in the live biotherapeutic product space targeting similar inflammatory and immuno-oncology indications.

TypeDirect peer
Description

European clinical-stage microbiome therapeutics company developing standardized, full-spectrum microbiome-based therapies for oncology and inflammatory diseases, including gut-augmenting approaches combined with immunotherapy. Comparable indication overlap and late-stage clinical development profile.

44D pharma
TypeDirect peer
Description

UK-based clinical-stage biotech developing single-strain live biotherapeutics for cancer and respiratory disease. Comparable to Microbiotica on company size, clinical-stage status, and live biotherapeutic modality.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company with a microbiome-based program (gastrin/IL-22 fusion) targeting inflammatory bowel disease. Operates in the same microbiome-therapeutics category with overlapping IBD focus.

TypeDirect peer
Description

Clinical-stage company developing oral, single-strain microbiome-based therapies for inflammatory diseases and oncology. Comparable in product format (oral microbial medicines) and clinical-stage positioning.

TypeBroad incumbent
Description

Established global biopharma with significant IBD franchise (REBYOTA, a microbiome-derived therapy, acquired via Rebiotix). Operates in the same IBD and microbiome-therapeutics space with broader portfolio scale.

TypeEmerging player
Description

Clinical-stage microbiome therapeutics company developing consortia-based treatments for inflammatory and infectious diseases. Comparable on technology platform and indication focus, though with narrower development pipeline.

TypeEmerging player
Description

Clinical-stage developer of defined microbial consortia targeting inflammatory diseases including IBD and asthma. Comparable product format and therapeutic area focus with similar clinical-stage maturity.

10Second Genome
TypeEmerging player
Description

Microbiome-focused drug discovery company using precision microbial science to identify therapeutic candidates for inflammatory and metabolic diseases. Comparable platform-driven approach to microbiome-based drug discovery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Microbiotica

Microbiome Therapeuticsmicrobiotica.com

Microbiotica is a Cambridge, UK-based clinical-stage biopharmaceutical company developing orally administered live biotherapeutic products (LBPs) for ulcerative colitis and immuno-oncology, using a proprietary clinic-led microbiome profiling platform to identify defined bacterial consortia with characterized mechanisms of action.

What Microbiotica does

Microbiotica Limited is a Cambridge, UK-based, clinical-stage biopharmaceutical company founded in 2016 as a spin-out from the Wellcome Sanger Institute. It develops orally administered live biotherapeutic products (LBPs), which are defined consortia of commensal gut bacteria, for inflammatory bowel disease and immuno-oncology. The lead asset MB310 is an eight-strain capsule for ulcerative colitis that delivered 63.2% clinical remission versus 30% on placebo in the Phase 1b COMPOSER-1 trial; MB097 is a nine-strain capsule being evaluated in combination with MSD's KEYTRUDA in advanced melanoma patients with primary resistance to anti-PD-1 therapy in the Phase 1b MELODY-1 trial.

The company's core technology is a clinic-led microbiome profiling platform that combines mass culturing, metagenomics and machine learning to identify bacteria associated with favorable outcomes in specific patient populations. MB310 has been characterized with three independent mechanisms of action, including a novel protein (IZOR) supporting gut barrier healing and immune regulation; MB097's strains induce dendritic-cell IL-12 production that drives cytotoxic T-cell and NK-cell tumor killing. The company has assembled an unusually rich clinical dataset, including the Cancer Research UK MELRESIST and MITRE studies (up to 1,800 patients) and samples from University of Adelaide FMT studies that seeded MB310.

Microbiotica is pre-revenue and funds operations from equity (over £62 million raised to date, including a $67 million 2022 Series B co-led by Tencent). The commercial model is licensing- and partnership-driven: the company relies on MSD for KEYTRUDA supply, the Crohn's & Colitis Foundation for cGMP manufacture of MB310, and previously executed a $534 million Genentech IBD collaboration. Customers are therefore strategic pharma partners rather than payers, and patients enrolled in clinical trials are end users, not revenue sources. Geographic footprint spans the UK, France, Italy, Spain, Austria, Bulgaria and Poland through trial sites.

Microbiotica firmographics

Firmographics
Name
Microbiotica
Legal name
Microbiotica Limited
Website
https://microbiotica.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Microbiotica is a Cambridge, UK-based clinical-stage biopharmaceutical company developing orally administered live biotherapeutic products (LBPs) for ulcerative colitis and immuno-oncology, using a proprietary clinic-led microbiome profiling platform to identify defined bacterial consortia with characterized mechanisms of action.
Ownership category
akta.pro rank

Microbiotica industry classification

Industry
Product category
Microbiome Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)

Keywords

  • Microbiome therapeutics
  • Live biotherapeutic products
  • Ulcerative colitis pipeline
  • Immuno-oncology microbiome
  • Defined bacterial consortia

Where Microbiotica is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Microbiotica business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Others

Revenue model

  1. Pharmaceutical Development: Pre-revenue clinical-stage biopharma company. Revenue generation anticipated through eventual product commercialization following regulatory approval, with potential licensing/partnership deals for late-stage development and commercialization rights.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Microbiotica product offering

Product offering

Core offering

Microbiotica discovers and develops precision microbiome medicines in the form of oral live biotherapeutic products (LBPs) - defined consortia of gut bacteria identified through its clinic-led discovery platform. Its lead clinical-stage assets are MB310 (eight-strain consortium) for mild-to-moderate ulcerative colitis and MB097 (nine-strain consortium) for advanced melanoma in combination with KEYTRUDA, both in Phase 1b clinical trials. The company's revenue path is through licensing, co-development and partnership agreements with pharmaceutical companies rather than direct product sales today.

Product overview

Microbiotica is a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs). The company operates a clinic-led discovery platform that uses microbiome profiling, bioinformatics, and machine learning to identify bacteria associated with favorable clinical outcomes in specific patient populations. The core product portfolio includes MB310, a defined consortium of eight bacterial strains for ulcerative colitis treatment, and MB097, a defined consortium of nine bacterial strains designed to enhance immune checkpoint inhibitor efficacy in advanced melanoma. Both products are orally administered live biotherapeutic products.

Differentiator

Problem solved

Functional benefit

Products and services

  • MB310 MB310 is Microbiotica's lead clinical asset: a once-daily, orally administered live biotherapeutic product (LBP) consisting of a defined consortium of eight strains of commensal gut bacteria, being developed as a precision microbiome medicine for mild-to-moderate ulcerative colitis. It is currently in the COMPOSER-1 Phase 1b clinical trial and has reported positive topline data including 63.2% clinical remission in the per-protocol population.
  • MB097 MB097 is Microbiotica's immuno-oncology live biotherapeutic product: a once-daily, orally administered LBP consisting of a defined consortium of nine strains of gut bacteria being developed in combination with MSD's KEYTRUDA (pembrolizumab) for advanced melanoma. It is in the MELODY-1 Phase 1b clinical trial and has reported positive results including an objective response rate approximately double that of pembrolizumab monotherapy, with a characterised IL-12 induction mechanism linked to the IZOR bacterial outer-membrane protein.

Quantifiable outcome

  • 63.2% clinical remission rate with MB310 vs 30% placebo in ulcerative colitis patients
  • +2 more outcomes

Companies that use Microbiotica

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Microbiotica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Microbiotica partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • University of AdelaidecoreStrategic or Co-development Partner · 18 June 2018Collaboration with Dr Sam Costello's team to analyze clinical samples from FMT study in UC patients. Led to identification of MB310 bacterial strains. Financial details not disclosed.
  • GenentechmajorStrategic or Co-development Partner · 1 January 2018$534 million strategic collaboration to discover, develop and commercialize biomarkers, targets and medicines for inflammatory bowel disease. Microbiotica delivered successfully microbial biomarker signatures of drug response. Now listed as previous collaboration.
  • MSD (Merck & Co., Inc.)coreStrategic or Co-development PartnerClinical trial supply collaboration where MSD supplies KEYTRUDA (pembrolizumab) for use in evaluating MB097 in combination with anti-PD-1 therapy in melanoma patients with primary resistance to immunotherapy. Microbiotica is study sponsor.
  • Crohn's & Colitis FoundationcoreStrategic or Co-development PartnerCollaboration supporting cGMP manufacture of MB310, enabling IND application and progression into first-in-human clinical trials. Foundation provides expertise and network in ulcerative colitis disease area.
  • Cancer Research UK and Cambridge University HospitalscoreStrategic or Co-development PartnerLandmark partnership to identify and develop microbiome co-therapies and biomarkers for cancer patients receiving immune checkpoint inhibitors. Includes MELRESIST melanoma study and MITRE study (1,800 patients) in melanoma, lung, and renal cancer.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Microbiotica competitors and assessment

Company assessment

Direct peers

  • Vedanta Biosciences: Clinical-stage biotech developing defined consortia of live bacteria for immune-mediated diseases including IBD and oncology indications. Closely comparable to Microbiotica on product format (defined bacterial consortia), target indications, and clinical-stage development profile.
  • Seres Therapeutics: Pioneer in microbiome therapeutics with FDA-approved VOWST for recurrent C. difficile infection and pipeline programs in IBD and oncology. Direct competitor in the live biotherapeutic product space targeting similar inflammatory and immuno-oncology indications.
  • MaaT Pharma: European clinical-stage microbiome therapeutics company developing standardized, full-spectrum microbiome-based therapies for oncology and inflammatory diseases, including gut-augmenting approaches combined with immunotherapy. Comparable indication overlap and late-stage clinical development profile.
  • 4D pharma: UK-based clinical-stage biotech developing single-strain live biotherapeutics for cancer and respiratory disease. Comparable to Microbiotica on company size, clinical-stage status, and live biotherapeutic modality.
  • Assembly Biosciences: Clinical-stage biopharmaceutical company with a microbiome-based program (gastrin/IL-22 fusion) targeting inflammatory bowel disease. Operates in the same microbiome-therapeutics category with overlapping IBD focus.
  • Evelo Biosciences: Clinical-stage company developing oral, single-strain microbiome-based therapies for inflammatory diseases and oncology. Comparable in product format (oral microbial medicines) and clinical-stage positioning.

Broad incumbents

  • Ferring Pharmaceuticals: Established global biopharma with significant IBD franchise (REBYOTA, a microbiome-derived therapy, acquired via Rebiotix). Operates in the same IBD and microbiome-therapeutics space with broader portfolio scale.

Emerging players

  • Finch Therapeutics: Clinical-stage microbiome therapeutics company developing consortia-based treatments for inflammatory and infectious diseases. Comparable on technology platform and indication focus, though with narrower development pipeline.
  • Siolta Therapeutics: Clinical-stage developer of defined microbial consortia targeting inflammatory diseases including IBD and asthma. Comparable product format and therapeutic area focus with similar clinical-stage maturity.
  • Second Genome: Microbiome-focused drug discovery company using precision microbial science to identify therapeutic candidates for inflammatory and metabolic diseases. Comparable platform-driven approach to microbiome-based drug discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Microbiotica social profiles

Digital presence

Microbiotica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Microbiotica leadership team

Management profile

Number of profiles

Profiles8 records

Microbiotica funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Microbiotica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Microbiotica

What does Microbiotica do?

Microbiotica discovers and develops precision microbiome medicines in the form of oral live biotherapeutic products (LBPs) - defined consortia of gut bacteria identified through its clinic-led discovery platform. Its lead clinical-stage assets are MB310 (eight-strain consortium) for mild-to-moderate ulcerative colitis and MB097 (nine-strain consortium) for advanced melanoma in combination with KEYTRUDA, both in Phase 1b clinical trials. The company's revenue path is through licensing, co-development and partnership agreements with pharmaceutical companies rather than direct product sales today.

Is Microbiotica a public or private company?

Microbiotica is a private company. It is classified as venture growth investor backed and is currently operating.

When was Microbiotica founded?

Microbiotica was founded in 2016. It employs 11 to 50 people.

Where is Microbiotica based?

Microbiotica is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Microbiotica make money?

One revenue line is on record: pharmaceutical Development.

Who are Microbiotica's main competitors?

Direct peers on record are Vedanta Biosciences, Seres Therapeutics, MaaT Pharma, 4D pharma, Assembly Biosciences and Evelo Biosciences. Ferring Pharmaceuticals is listed as a broad incumbent. Emerging players are Finch Therapeutics, Siolta Therapeutics and Second Genome.

Does Microbiotica have an API?

No public API is recorded for Microbiotica.

What industry is Microbiotica in?

Microbiotica's product category is Microbiome Therapeutics. Its primary akta.pro industry code is HLAAAFAK, Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling), with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialMicrobiotica Presents Phase 1B Clinical Data On MB097 At The European Society For Medical Oncology (ESMO) Congress 2026Microbiotica presented Phase 1b data on MB097 at ESMO 2026, showing the live biotherapeutic was safe with KEYTRUDA in advanced melanoma. Three of 21 patients (14%) in the vancomycin-preconditioning arm achieved objective responses, versus two of 20 (10%) in the non-vancomycin arm. The company plans further evaluation in an extension phase.GlobeNewswireMicrobiotica Presents Phase 1b Clinical Data on MB097 at the European Society for Medical Oncology (ESMO) Congress 2026Microbiotica presented Phase 1b MELODY-1 trial data for MB097 in advanced melanoma at ESMO 2026, meeting all endpoints. The nine-strain live biotherapeutic was safe with KEYTRUDA, and 14% of vancomycin-preconditioned patients achieved objective responses, including deep regressions. The company plans further evaluation in an extension phase.Startup ResearcherMicrobiotica Secures £36 Million Series C First CloseMicrobiotica closed a £36 million Series C round led by the British Business Bank, with participation from Tencent and others. The funds will advance MB310 into Phase 2 clinical development for ulcerative colitis, following positive Phase 1b results. The company also has a pipeline including MB097 for melanoma.The Pharma LetterMicrobiotica raises $48 million to support MB310 developmentMicrobiotica, a UK clinical-stage biopharma company, closed a £36 million ($48 million) Series C financing led by British Business Bank. The round included participation from Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, and Seventure Partners, with all existing Series B investors participating.EU-StartupsNew treatment for inflammatory bowel disease lands Microbiotica €42 millionMicrobiotica closed a €42 million Series C financing led by British Business Bank, with participation from Tencent and others. The funds will advance MB310 into Phase 2 clinical development for ulcerative colitis, following positive Phase 1b results. The company also plans to develop MB097 for advanced melanoma.InvestegateMicrobiotica raises £36m in Series C financingMicrobiotica raised £36m in a Series C financing round, with IP Group investing £4m. The funding will advance its MB310 program into Phase 2 clinical development for ulcerative colitis, following positive Phase 1b results. IP Group's holding will be 16.4%.Sharecast.comIP Group invests £4m in portfolio company Microbiotica financing roundMicrobiotica closed a £36m financing round, with IP Group investing £4m. The funds will advance its ulcerative colitis treatment into a phase two trial after a phase 1b study showed statistically significant improvements versus placebo. IP Group holds a 16.4% undiluted stake valued at £24.1m.EIN PresswireMicrobiotica raises £36m for cutting-edge IBD treatmentMicrobiotica raised £36m in a Series C led by British Business Bank, with participation from Tencent and others. Proceeds will advance its lead asset MB310 into Phase 2 clinical development for ulcerative colitis, following positive Phase 1b results. The company also has a pipeline including MB097 for melanoma.BusinessCloudMicrobiotica raises £36m for cutting-edge IBD treatmentMicrobiotica raised £36m in a Series C led by British Business Bank, with participation from Tencent and others. Proceeds will advance its lead asset MB310 into Phase 2 clinical development for ulcerative colitis, following positive Phase 1b results. The company also has a pipeline including MB097 for melanoma.GlobeNewswireMicrobiotica Raises £36 Million ($48 Million) in Series C Financing to Advance Pipeline into Phase 2 Clinical DevelopmentMicrobiotica raised £36 million ($48 million) in a Series C financing led by British Business Bank. Proceeds will advance MB310 into Phase 2 clinical development for ulcerative colitis, following positive Phase 1b results. The company also has an immuno-oncology pipeline asset MB097.